Efficacy and safety of currently approved and lower starting doses of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukemia: a phase IV study

Efficacy and safety of currently approved and lower starting doses of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukemia: a phase IV study

Inotuzumab ozogamicin (InO) is approved for treatment of relapsed/refractory acute lymphoblastic leukemia (R/R ALL). Previous studies reported higher rates of post– hematopoietic stem cell transplant (HSCT) hepatic sinusoidal obstruction syndrome (SOS) in patients receiving InO versus chemotherapy...

Full description

Saved in:
Bibliographic Details
Main Authors: Muhit Özcan, Ryan D. Cassaday, Ewa Zarzycka, Erik Vandendries, Fan Zhang, Ying Chen, Alejandra Nieto, Fatih Demirkan, Pau Montesinos, Fevzi Altuntas
Format: Article
Language:English
Published: Ferrata Storti Foundation 2025-01-01
Series:Haematologica
Online Access:https://haematologica.org/article/view/11921
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://haematologica.org/article/view/11921

Similar Items